Stocks quoted in this article:
Analysts are weighing in today on telecom issue JDS Uniphase Corp (NASDAQ:JDSU - 13.16), and drug makers Infinity Pharmaceuticals Inc. (NASDAQ:INFI - 34.08) and Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR - 25.25). Here's a quick roundup of today's bullish brokerage notes.
- JDSU -- which has gained about 26% so far this year -- received a price-target hike to $16 from $12 at Piper Jaffray this morning. Meanwhile, short-term bulls seem to have confidence in the security, as well. Schaeffer's put/call open interest ratio (SOIR) for JDSU checks in at 0.35, with calls nearly tripling puts among options scheduled to expire within the next three months. This ratio hovers just 2 percentage points above a yearly low, meaning near-term traders have rarely been more call-heavy toward the equity during the past year.
- Up a whopping 286% year-to-date, INFI saw its price target lifted to $38 from $32 at RBC ahead of the opening bell. However, despite the stock's technical prowess, puts have been heavily favored over calls lately. In fact, data pulled from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows a 10-day put/call volume ratio of 5.36 for INFI. In other words, speculators have bought to open 536 puts for every 100 calls during the last two weeks.
- AEGR scored an upward price-target adjustment to $30 from $27 at Capstone today, on the heels of receiving approval from the Food and Drug Administration (FDA) for its Juxtapid drug. The security has climbed nearly 51% in 2012 -- while also besting the broader S&P 500 Index (SPX) by almost 74 percentage points during the past three months -- yet there is still plenty of skepticism surrounding AEGR. Short interest accounts for more than 11% of the equity's available float. It would take roughly six days to cover these shorted shares, at the stock's average pace of trading.